Lapatinib could be used to treat patients with aggressive inflammatory breast cancer

April 26, 2009

Lapatinib could be used to treat inflammatory breast cancer, an aggressive from of the disease which represents up to one tenth of malignant breast cancer cases. The findings of this phase II study are discussed in an Article published Online First and in the June edition of the Lancet Oncology, written by Dr Stephen Johnston, Royal Marsden Hospital, London, UK, and Dr Bella Kaufman, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and colleagues.

Inflammatory breast cancer makes up 1-6% of all invasive breast tumours in the USA and western Europe, and 5-10% in North Africa and Arabian countries. In this form of cancer, the protein human epidermal growth factor receptor 2 (HER2) -- which is involved in the signaling pathways leading to cell growth -- is expressed much more than in other, less aggressive breast cancers. Clinical symptoms are rapid onset of swelling, redness of the breast skin, fluid under the skin of more than two thirds of the breast which can result in a pitted appearance, tenderness, hardening, and warming of the breast.

For patients with resistance to conventional anthracycline or taxane and trastuzumab treatment, options are limited. Lapatinib is an oral inhibitor of HER2 and thus interferes with the mechanism of tumour growth. This study assessed 126 patients, all with inflammatory breast cancer, who were treated with lapatinib 1500 mg once daily. Skin disease was assessed every four weeks, and cancer progression, both local and secondary, was assessed using standard criteria.

The researchers found that although no patient showed complete response to the treatment, 49 of them (39%) had a partial response (a 50% decrease in extent of skin disease from baseline). Median progression-free survival was 15 weeks, with median duration of response 21 weeks. At 6 months, 22% of patients were still progression-free. Likelihood of response to lapatinib was not affected by previous treatment with trastuzumab. Median overall survival was recorded for four sets of patients: responded to lapatinib, previous trastuzumab (33 patients) -- 18.4 months; responded to lapatinib, no previous trastuzumab (15) -- 14.0 months; unresponsive to lapatinib, previous trastuzumab (61) -- 8.4 months; and finally unresponsive to lapatinib, no previous trastuzumab (16) -- 8.2 months. Adverse events were common, with 92% of patients suffering at least one. 32% of patients had serious adverse events most of which were not considered to be related to lapatinib -- the most common of these were shortness of breath (eight patients) and fluid around the lungs (six). Five patients died from adverse events that were possibly treatment related.

The authors say: "Patients who responded to treatment with lapatinib had a longer median overall survival than did those patients who did not respond, irrespective of previous exposure to trastuzumab. Patients exposed to previous trastuzumab treatment who experienced a response to lapatinib had the longest median overall survival. This finding confirms the clinical benefit of targeted therapy in these patients."

They conclude: "Lapatinib monotherapy is potentially clinically effective in heavily pretreated patients with inflammatory breast cancer with HER2+ tumours. The objective response rate noted...coupled with the median duration of response and median overall survival supports a role for lapatinib in these patients."
For Dr Stephen Johnston, Royal Marsden Hospital, London UK please contact Press Office T) +44 (0) 207 808 2383 E) /

Dr Bella Kaufman, The Chaim Sheba Medical Center, Tel Hashomer, Israel T) +972 526667144 E)

For full Article, see:


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to